BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121:4382-4388. [PMID: 26440929 DOI: 10.1002/cncr.29664] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 17.2] [Reference Citation Analysis]
Number Citing Articles
1 Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery 2021;169:629-35. [PMID: 32826069 DOI: 10.1016/j.surg.2020.06.038] [Reference Citation Analysis]
2 Choi YH, Lim Y, Ryu JK, Paik WH, Lee SH, Kim YT, Kim JH. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer. Cancers (Basel) 2021;13:1196. [PMID: 33801891 DOI: 10.3390/cancers13061196] [Reference Citation Analysis]
3 Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book. 2019;39:79-86. [PMID: 31099688 DOI: 10.1200/edbk_238977] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
4 Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. JAMA Oncol. 2020;6:764-771. [PMID: 32053139 DOI: 10.1001/jamaoncol.2019.5963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
5 Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol 2020;38:1442-54. [PMID: 32073954 DOI: 10.1200/JCO.19.01890] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
6 Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Cancer 2019;125:2488-96. [PMID: 30980401 DOI: 10.1002/cncr.32077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Crowley F, Park W, O'Reilly EM. Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev 2021. [PMID: 34403012 DOI: 10.1007/s10555-021-09983-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J, Yuan Y. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep 2016;6:36073. [PMID: 27782199 DOI: 10.1038/srep36073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 2020;122:333-9. [PMID: 31787751 DOI: 10.1038/s41416-019-0582-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 19.0] [Reference Citation Analysis]
11 Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev 2019;80:101895. [PMID: 31542591 DOI: 10.1016/j.ctrv.2019.101895] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00152] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
14 Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open 2021;6:100032. [PMID: 33399070 DOI: 10.1016/j.esmoop.2020.100032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pittman ME, Brosens LA, Wood LD. Genetic Syndromes with Pancreatic Manifestations. Surg Pathol Clin. 2016;9:705-715. [PMID: 27926368 DOI: 10.1016/j.path.2016.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
16 Southey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. Hered Cancer Clin Pract 2016;14:9. [PMID: 27099641 DOI: 10.1186/s13053-016-0049-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
17 Chen F, Childs EJ, Mocci E, Bracci P, Gallinger S, Li D, Neale RE, Olson SH, Scelo G, Bamlet WR, Blackford AL, Borges M, Brennan P, Chaffee KG, Duggal P, Hassan MJ, Holly EA, Hung RJ, Goggins MG, Kurtz RC, Oberg AL, Orlow I, Yu H, Petersen GM, Risch HA, Klein AP. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Cancer Epidemiol Biomarkers Prev 2019;28:1238-45. [PMID: 31015203 DOI: 10.1158/1055-9965.EPI-18-1235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
18 Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci 2020;111:3111-21. [PMID: 32639661 DOI: 10.1111/cas.14565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Teo MY, O'Reilly EM. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 2016;7:738-49. [PMID: 27747088 DOI: 10.21037/jgo.2016.05.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Zohar L, Rottenberg Y, Twig G, Katz L, Leiba A, Derazne E, Tzur D, Eizenstein S, Keinan-Boker L, Afek A, Kark JD. Adolescent overweight and obesity and the risk for pancreatic cancer among men and women: a nationwide study of 1.79 million Israeli adolescents. Cancer. 2019;125:118-126. [PMID: 30417331 DOI: 10.1002/cncr.31764] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
21 Liang Z, Hu W, Li S, Wei Z, Zhu Z. Germline BRCA2 Truncating Mutation in Familial Esophageal Squamous Cell Carcinoma: A Case Controlled Study in China. Med Sci Monit 2020;26:e923926. [PMID: 32579544 DOI: 10.12659/MSM.923926] [Reference Citation Analysis]
22 Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019;75:27-38. [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
23 Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC. Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:E198. [PMID: 33429865 DOI: 10.3390/cancers13020198] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Bujanda L, Herreros-Villanueva M. Pancreatic Cancer in Lynch Syndrome Patients. J Cancer 2017;8:3667-74. [PMID: 29151953 DOI: 10.7150/jca.20750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
26 Peters MLB, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics 2016;38:1622-35. [DOI: 10.1016/j.clinthera.2016.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
27 McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta 2016;1863:2942-76. [PMID: 27612668 DOI: 10.1016/j.bbamcr.2016.09.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 17.0] [Reference Citation Analysis]
28 Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8:73240-73257. [PMID: 29069866 DOI: 10.18632/oncotarget.17291] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
29 de Almeida LC, Calil FA, Machado-neto JA, Costa-lotufo LV. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. Cancer Genetics 2021;252-253:6-24. [DOI: 10.1016/j.cancergen.2020.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
30 Park JK, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. Cancers (Basel) 2021;13:2791. [PMID: 34205170 DOI: 10.3390/cancers13112791] [Reference Citation Analysis]
31 Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 2019;21:213-23. [PMID: 29961768 DOI: 10.1038/s41436-018-0009-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 21.7] [Reference Citation Analysis]
32 Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016;10:893-905. [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
33 Zhu H, Welinsky S, Soper ER, Brown KL, Abul-Husn NS, Lucas AL. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing. Pancreas 2021;50:602-6. [PMID: 33939675 DOI: 10.1097/MPA.0000000000001804] [Reference Citation Analysis]
34 Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, Sevcik J, Kleibl Z, Janatova M. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genetics 2016;209:199-204. [DOI: 10.1016/j.cancergen.2016.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
35 Langner C. Hereditäres Magen- und Pankreaskarzinom. Pathologe 2017;38:164-9. [DOI: 10.1007/s00292-017-0297-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
36 Akbari MR, Gojska N, Narod SA. Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer. Curr Oncol 2017;24:282-3. [PMID: 29089794 DOI: 10.3747/co.24.3828] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
37 Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers (Basel) 2018;10:E17. [PMID: 29329208 DOI: 10.3390/cancers10010017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
38 Wang XY, Chen HT, Na R, Jiang DK, Lin XL, Yang F, Jin C, Fu DL, Xu JF. Single-nucleotide polymorphisms based genetic risk score in the prediction of pancreatic cancer risk. World J Gastroenterol 2020;26:3076-86. [PMID: 32587449 DOI: 10.3748/wjg.v26.i22.3076] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
40 Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther 2019;12:3387-400. [PMID: 31118690 DOI: 10.2147/OTT.S176700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
41 Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1 , BRCA2 , PALB2 , and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00098] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
42 Underhill ML, Germansky KA, Yurgelun MB. Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther 2016;38:1600-21. [PMID: 27045993 DOI: 10.1016/j.clinthera.2016.03.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
43 Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N, Iwata K, Okuno M, Mukai T, Shimizu M. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J Clin Med 2019;8:E761. [PMID: 31146420 DOI: 10.3390/jcm8060761] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
44 Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford) 2020;22:1745-52. [PMID: 32354656 DOI: 10.1016/j.hpb.2020.03.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Doran AG, Wong K, Flint J, Adams DJ, Hunter KW, Keane TM. Deep genome sequencing and variation analysis of 13 inbred mouse strains defines candidate phenotypic alleles, private variation and homozygous truncating mutations. Genome Biol 2016;17:167. [PMID: 27480531 DOI: 10.1186/s13059-016-1024-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
46 Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine 2016;8:30-9. [PMID: 27428416 DOI: 10.1016/j.ebiom.2016.04.017] [Cited by in Crossref: 119] [Cited by in F6Publishing: 82] [Article Influence: 23.8] [Reference Citation Analysis]
47 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
48 Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol 2017;35:3382-90. [PMID: 28767289 DOI: 10.1200/JCO.2017.72.3502] [Cited by in Crossref: 167] [Cited by in F6Publishing: 86] [Article Influence: 41.8] [Reference Citation Analysis]
49 Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 2018;89:19-26. [PMID: 29223478 DOI: 10.1016/j.ejca.2017.11.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 18.5] [Reference Citation Analysis]
50 Gupta M, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers (Basel) 2019;11:E1980. [PMID: 31835379 DOI: 10.3390/cancers11121980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
51 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
52 Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol 2021;56:713-21. [PMID: 34255164 DOI: 10.1007/s00535-021-01806-y] [Reference Citation Analysis]
53 Goehringer C, Sutter C, Kloor M, Gebert J, Slater EP, Keller M, Treiber I, Ganschow P, Kadmon M, Moog U. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor. Fam Cancer 2017;16:303-9. [PMID: 27838800 DOI: 10.1007/s10689-016-9952-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
54 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
55 Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer 2018;18:697. [PMID: 29945567 DOI: 10.1186/s12885-018-4573-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
56 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
57 Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. J Clin Oncol 2021;39:2617-31. [PMID: 34197182 DOI: 10.1200/JCO.20.03238] [Reference Citation Analysis]
58 Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6:58. [PMID: 29307198 DOI: 10.21037/cco.2017.12.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
59 Chiaravalli M, Reni M, O'reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews 2017;60:32-43. [DOI: 10.1016/j.ctrv.2017.08.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 19.0] [Reference Citation Analysis]
60 Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E193. [PMID: 29891787 DOI: 10.3390/cancers10060193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
61 Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res 2017;77:1510-41. [PMID: 28373404 DOI: 10.1158/0008-5472.CAN-16-2346] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 18.3] [Reference Citation Analysis]
62 Cremin C, Lee MK, Hong Q, Hoeschen C, Mackenzie A, Dixon K, McCullum M, Nuk J, Kalloger S, Karasinska J, Scudamore C, Kim PTW, Donnellan F, Lam ECS, Lim HJ, Neben CL, Stedden W, Zhou AY, Schaeffer DF, Sun S, Renouf DJ, Schrader KA. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med 2020;9:4004-13. [PMID: 32255556 DOI: 10.1002/cam4.2973] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
63 Yurgelun MB, Chenevix-trench G, Lippman SM. Translating Germline Cancer Risk into Precision Prevention. Cell 2017;168:566-70. [DOI: 10.1016/j.cell.2017.01.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
64 Slater EP, Wilke LM, Böhm LB, Strauch K, Lutz M, Gercke N, Matthäi E, Hemminki K, Försti A, Schlesner M, Paramasivam N, Bartsch DK. Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer. J Pers Med 2021;11:631. [PMID: 34357098 DOI: 10.3390/jpm11070631] [Reference Citation Analysis]
65 Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. J Natl Cancer Inst 2018;110:1067-74. [PMID: 29506128 DOI: 10.1093/jnci/djy024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 60] [Article Influence: 41.0] [Reference Citation Analysis]
66 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
67 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
68 Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs 2018;28:161-77. [DOI: 10.1080/13543784.2019.1557145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
69 Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition. Int J Mol Sci 2017;18:E1886. [PMID: 28858227 DOI: 10.3390/ijms18091886] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
70 Stoffel EM, Mckernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M, Khorana AA. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. JCO 2019;37:153-64. [DOI: 10.1200/jco.18.01489] [Cited by in Crossref: 48] [Cited by in F6Publishing: 10] [Article Influence: 24.0] [Reference Citation Analysis]
71 Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Gausman V, Kandel P, Van Riet PA, Moris M, Kayal M, Do C, Poneros JM, Sethi A, Gress FG, Schrope BA, Luk L, Hecht E, Jovani M, Bruno MJ, Cahen DL, Wallace MB, Gonda TA. Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort. Pancreas 2018;47:471-6. [PMID: 29521942 DOI: 10.1097/MPA.0000000000001027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
73 Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol 2017;116:25-34. [PMID: 28591939 DOI: 10.1002/jso.24623] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
74 Dudley B, Karloski E, Monzon FA, Singhi AD, Lincoln SE, Bahary N, Brand RE. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy: Mutations in Selected Pancreatic Cancers. Cancer 2018;124:1691-700. [DOI: 10.1002/cncr.31242] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
75 Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer 2019;120:848-54. [PMID: 30867564 DOI: 10.1038/s41416-019-0426-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Verbeke C. Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter? Pancreatology. 2016;16:295-301. [PMID: 26924665 DOI: 10.1016/j.pan.2016.02.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
77 Lee K, Yoo C, Kim KP, Park KJ, Chang HM, Kim TW, Lee JL, Lee W, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Invest New Drugs 2018;36:163-9. [PMID: 28782087 DOI: 10.1007/s10637-017-0497-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Saldia A, Olson SH, Nunes P, Liang X, Samson ML, Salo-Mullen E, Marcell V, Stadler ZK, Allen PJ, Offit K, Kurtz RC. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prev Res (Phila) 2019;12:599-608. [PMID: 31337648 DOI: 10.1158/1940-6207.CAPR-18-0272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Nepomuceno TC, Carvalho MA, Rodrigue A, Simard J, Masson JY, Monteiro ANA. PALB2 Variants: Protein Domains and Cancer Susceptibility. Trends Cancer 2021;7:188-97. [PMID: 33139182 DOI: 10.1016/j.trecan.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021. [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9] [Reference Citation Analysis]
81 Yurgelun MB. Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. JCO 2017;35:3375-7. [DOI: 10.1200/jco.2017.74.7535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]